The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients

NCT06357806 · clinicaltrials.gov ↗

NA

Phase

ACTIVE_NOT_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Chronic Hepatitis B

Interventions

DRUG: Sintilimab
DRUG: Peg-IFNα-2b
DRUG: NAs

Sponsor

Beijing 302 Hospital